PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today reported the publication of a study by independent investigators evaluating the safety and efficacy of QUADRAMET® (samarium Sm-153 lexidronam injection) in combination with chemotherapy for the treatment of patients with hormone-refractory prostate cancer (HRPC). The publication, “Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer” by Ricci, S. et al., appeared in the online issue of the European Journal of Nuclear Medicine and Molecular Imaging (Eur J Nucl Med Mol Imaging. 2007 Jan 23), the official journal of the European Association of Nuclear Medicine (EANM).
